Literature DB >> 7656668

Effect of ebselen on renal scarring in rats following renal infection.

M Haraoka1, T Matsumoto, Y Mizunoe, K Takahashi, S Kubo, Y Koikawa, M Tanaka, Y Sakamoto, M Sakumoto, T Nagafuji.   

Abstract

Renal scarring, which occurs following refluxing pyelonephritis, is considered to be involved in the development of reflux nephropathy. Prevention of renal scar formation requires immediate initiation of antimicrobial treatment; treatment delay results in renal scarring. We demonstrate that Ebselen, an antioxidant agent, given at a dose of 15 mg/kg twice a day prevents renal scarring in rats following direct renal parenchymal bacterial inoculation. In addition, using an ascending pyelonephritis model, which clinically resembles refluxing pyelonephritis in humans, we show that when initiation of antimicrobial treatment was delayed, coadministration of Ebselen prevents renal scar formation. These results show that Ebselen is effective in preventing renal scarring and suggest that the clinical use of this drug may prevent renal scar formation following pyelonephritis and progression to reflux nephropathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656668     DOI: 10.1159/000239346

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  The effect of vitamin A on renal damage following acute pyelonephritis in children.

Authors:  Parviz Ayazi; Seyed Alireza Moshiri; Abolfazl Mahyar; Mona Moradi
Journal:  Eur J Pediatr       Date:  2010-09-18       Impact factor: 3.183

Review 2.  The effect of vitamin A on renal damage following acute pyelonephritis in children: a meta-analysis of randomized controlled trials.

Authors:  Guo-Qiang Zhang; Jin-Liang Chen; Yong Zhao
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

3.  Ebselen improves ischemia-reperfusion injury after rat lung transplantation.

Authors:  Jürg Hamacher; Uz Stammberger; Elvira Weber; Rudolf Lucas; Albrecht Wendel
Journal:  Lung       Date:  2009-02-07       Impact factor: 2.584

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.